Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016219622AAU2016219622A1 (en) | 2010-04-20 | 2016-08-24 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
AU2018201503AAU2018201503A1 (en) | 2010-04-20 | 2018-03-01 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
AU2019283898AAU2019283898C1 (en) | 2010-04-20 | 2019-12-18 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
AU2022201608AAU2022201608B2 (en) | 2010-04-20 | 2022-03-08 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201000330 | 2010-04-20 | ||
US61/326,082 | 2010-04-20 | ||
DKPA201001066 | 2010-11-24 | ||
AU2013203221AAU2013203221B2 (en) | 2010-04-20 | 2013-04-09 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
AU2016219622AAU2016219622A1 (en) | 2010-04-20 | 2016-08-24 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2013203221ADivisionAU2013203221B2 (en) | 2010-04-20 | 2013-04-09 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2018201503ADivisionAU2018201503A1 (en) | 2010-04-20 | 2018-03-01 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
Publication Number | Publication Date |
---|---|
AU2016219622A1true AU2016219622A1 (en) | 2016-09-15 |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2016219622AAbandonedAU2016219622A1 (en) | 2010-04-20 | 2016-08-24 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
AU2018201503AAbandonedAU2018201503A1 (en) | 2010-04-20 | 2018-03-01 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
AU2019283898AActiveAU2019283898C1 (en) | 2010-04-20 | 2019-12-18 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2018201503AAbandonedAU2018201503A1 (en) | 2010-04-20 | 2018-03-01 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
AU2019283898AActiveAU2019283898C1 (en) | 2010-04-20 | 2019-12-18 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
Country | Link |
---|---|
AU (3) | AU2016219622A1 (en) |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI544076B (en)* | 2005-03-31 | 2016-08-01 | Chugai Pharmaceutical Co Ltd | A method of manufacturing a polypeptide that controls assembly |
PL2235064T3 (en)* | 2008-01-07 | 2016-06-30 | Amgen Inc | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
Publication number | Publication date |
---|---|
AU2019283898A1 (en) | 2020-01-23 |
AU2019283898B2 (en) | 2021-12-09 |
AU2018201503A1 (en) | 2018-03-22 |
AU2019283898C1 (en) | 2022-06-16 |
Publication | Publication Date | Title |
---|---|---|
EP4477668A3 (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
WO2010145792A8 (en) | Bispecific antigen binding proteins | |
MX336682B (en) | Antibodies against human csf-1r and uses thereof. | |
MX356337B (en) | Antibodies against human csf-1r and uses thereof. | |
SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
SG10201805291TA (en) | Production of heterodimeric proteins | |
AU2014247175A8 (en) | Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use | |
NZ630568A (en) | Methods and means for the production of ch3 domain-comprising molecules | |
MX2019003427A (en) | Cell culture compositions and methods for polypeptide production. | |
MY170720A (en) | Antibody formulations | |
MX359384B (en) | Improved assembly of bispecific antibodies. | |
WO2013188693A8 (en) | Antigen binding constructs to cd3 | |
EA201171148A1 (en) | ANTI-TELE-ANTAGONIST, SPECIFIC FOR THE ALPHA-4-BETA-7 HETERODIMER | |
MX342034B (en) | Monovalent antigen binding proteins. | |
WO2009114702A3 (en) | Recombinant production of authentic human proteins using human cell expression systems | |
WO2012064836A9 (en) | Methods and compositions for neural disease immunotherapy | |
EP4375371A3 (en) | Methods for the manufacture of proteolytically processed polypeptides | |
WO2012068317A3 (en) | Methods for producing recombinant proteins | |
MX2015011781A (en) | Cell culture media and methods of antibody production. | |
WO2010121093A3 (en) | Humanized antibody compositions and methods for binding lysophosphatidic acid | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
EP4458858A3 (en) | Method for the production of immunoglobulin single variable domains | |
WO2010079510A3 (en) | Anti-rhd monoclonal antibodies | |
MX2016001678A (en) | Expression constructs and methods for expressing polypeptides in eukaryotic cells. |
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |